Postoperative radiotherapy of patients with thymic epithelial tumors (TET)

详细信息    查看全文

• 作者：Dr. med. Matthias Felix H?fner M.D.…
• 关键词：Radiotherapy ; adjuvant ; Thymoma ; Thymic epithelial tumors ; Postoperative care ; Thyroid neoplasms ; Adjuvante Radiotherapie ; Thymom ; Epitheliales Thymuskarzinom ; Postoperative Versorgung ; Thymusneoplasie
• 刊名：Strahlentherapie und Onkologie
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：191
• 期：2
• 页码：133-140
• 全文大小：530 KB
• 参考文献：1. Engels EA, Pfeiffer RM (2003) Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546-51 CrossRef
  2. Chen YD, Feng QF, Lu HZ et al (2010) Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 78:1400-406 CrossRef
  3. Zhu G, He S, Fu X et al (2004) Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys 60:1113-119 CrossRef
  4. Kondo K, Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76:878-84 (discussion 884-75) CrossRef
  5. Curran WJ Jr, Kornstein MJ, Brooks JJ et al (1988) Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6:1722-727
  6. Forquer JA, Rong N, Fakiris AJ et al (2010) Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 76:440-45 CrossRef
  7. Fuller CD, Ramahi EH, Aherne N et al (2010) Radiotherapy for thymic neoplasms. J Thorac Oncol 5:S?327-35 CrossRef
  8. Korst RJ, Kansler AL, Christos PJ et al (2009) Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 87:1641-647 CrossRef
  9. Masaoka A, Monden Y, Nakahara K et al (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485-492 CrossRef
  10. Masaoka A, Yamakawa Y, Niwa H et al (1994) Thymectomy and malignancy. Eur J Cardiothorac Surg 8:251-53 CrossRef
  11. Rosai J (1999) Histological typing of tumours of the thymus. Springer, New York CrossRef
  12. Strobel P, Marx A, Zettl A et al (2005) Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 35:805-11 CrossRef
  13. Levine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 9:495-15 CrossRef
  14. Marchevsky AM, Gupta R, Mckenna RJ et al (2008) Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 112:2780-788 CrossRef
  15. Wu KL, Mao JF, Chen GY et al (2009) Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: a study of 241 patients. Cancer Invest 27:1008-015 CrossRef
  16. Patel S, Macdonald OK, Nagda S et al (2012) Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys 82:1797-801 CrossRef
  17. Kundel Y, Yellin A, Popovtzer A et al (2007) Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. Am J Clin Oncol 30:389-94 CrossRef
  18. Chang JH, Kim HJ, Wu HG et al (2011) Postop
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Radiotherapy
  Oncology
  
• 出版者：Urban & Vogel
• ISSN：1439-099X

文摘

Purpose The purpose of this study was to evaluate postoperative radiotherapy regarding outcome and toxicity in patients with thymic epithelial tumors (TET) after surgery. Materials and methods We retrospectively analyzed medical records of 41?patients with TET treated with postoperative radiotherapy at our institution between 1995 and 2012. The impact of prognostic factors (e.g., Masaoka stage, histological subtype) was investigated and radiation-related toxicity was assessed. Results Median age was 59.8?years and median follow-up was 61?months. In 24.4-, TETs were associated with paraneoplastic syndromes. The 5-year overall survival (OS) was 89.5- and the 5-year disease-free survival (DFS) was 88.9-. Masaoka stage had a significant impact on OS (p--.007). Locally limited stages I-?II had a 5-year OS of 100- compared to 80- for stage?III and 66.7- for stage?IV. The 5-year DFS was excellent with 100- for both WHO groups A/AB/B1 and B2, respectively, and significantly (p--.005) differed from B3/C-staged patients with a 5-year DFS of 63.6-. Resection status, paraneoplastic association, radiation dose, or tumor size did not influence survival. There were no high-grade acute or late side effects caused by radiotherapy. Conclusion Masaoka stage has a significant impact on OS as WHO type has on DFS in patients with TETs after surgery and adjuvant irradiation. Postoperative radiotherapy with doses around 50?Gy is safe and not likely to cause high-grade toxicity. Further prospective trials are necessary to separate patient subgroups that benefit from radiotherapy from those that do not.